Under the three-year deal, the partnership will use insitro’s platform to create disease models for NASH and discover targets that can impact clinical progression and regression of the
The post Gilead, insitro collaborate to develop therapies for nonalcoholic steatohepatitis appeared first on Pharmaceutical Business review.